VWF-GPIb Interaction Screening via Recombinant Protein Assay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current screening processes for diagnosing von Willebrand syndrome and platelet-type von Willebrand disease are inadequate in detecting disorders in the interaction between von Willebrand factor (VWF) and glycoprotein Ib (GPIb), which can lead to hemorrhagic tendencies, as they are either not sensitive enough or require multiple assays to determine the exact cause of hemorrhagic disorders.
Innovation Solution
A screening process involving contacting a patient sample with isolated GPIb.alpha. protein and VWF protein, along with a solid phase associated with a GPIb.alpha.-specific antibody, to determine complex formation and detect disorders in VWF-GPIb interaction, which can be quantitative or qualitative, and is sensitive to both VWF and GPIb protein disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional screening processes (bleeding time, VWF:Ag, VWF:RCo) are used, then diagnosis of von Willebrand syndrome can be performed, but they are not sensitive enough to detect disorders in VWF-GPIb interaction
Solution Approach 1:
The patent introduces an intermediary substance ( ristocetin or botrocetin) that mediates the interaction between VWF and GPIb, enabling the detection of VWF-GPIb interaction disorders. This intermediary facilitates binding between VWF and GPIb.alpha., allowing the assay to detect functional interactions that conventional methods miss.
Solution Approach 2:
The patent uses recombinant GPIb.alpha. protein as a copy or surrogate for the native platelet membrane GPIb-IX complex. This recombinant protein copy allows direct measurement of VWF binding to GPIb without requiring intact platelets, thereby improving detection sensitivity while maintaining diagnostic relevance.
2Adaptability or versatility
If multiple assays are used to determine the exact cause of hemorrhagic disorders, then diagnostic coverage is improved, but process complexity increases
Solution Approach 1:
The patent creates a universal assay platform that can detect multiple types of VWF-GPIb interaction disorders (quantitative VWF deficiencies, qualitative VWF disorders, GPIb mutations, and inhibitors) through a single test system. This multi-functional assay eliminates the need for multiple separate tests while maintaining comprehensive diagnostic coverage.
Solution Approach 2:
The patent segments the diagnostic process by using a specific assay (VWF binding to GPIb.alpha.) that directly targets the functional interaction defect, rather than requiring multiple indirect tests. This segmentation allows focused detection of VWF-GPIb interaction disorders specifically.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process effectively detects VWF-GPIb interaction disorders by measuring altered complex formation, allowing for the identification of specific disorders that may be caused by inhibitors, activators, or qualitative issues in either VWF or GPIb, facilitating targeted therapy.
Implementation Method 1
contacting the sample with GPIb.alpha. protein, with VWF protein and with a solid phase associated with an antibody specific for said isolated GPIb.alpha. protein, and determining formation of a complex between VWF protein, GPIb.alpha. protein and the solid phase
Data Source
AI summary
The invention relates to a screening process for determining a disordered von Willebrand factor (VWF)-GPIb interaction in a patient's sample. This comprises contacting the sample with isolated GPIb.alpha. protein, with VWF protein and with a solid phase associated with an antibody specific for said isolated GPIb.alpha. protein, and determining complex formation.